Member Info for mohdburhan314

To many interviews - To much pumping without any concrete medical data & evidence. Invest only you can afford to lose.

Seems lots of ramping going on here. Only invest what you can afford to lose.

Only invest what you can afford to lose.. In my experience in AIM - Trends are not your Friends -

Hello ,

What’s the current financial situation of the company.

Do they need any money to raised to move further to drill

You will not see this price again - 1p back soon

Can you please help me with my queries

Any 5 reasons to buy this stock?

What is the current financial situation.

Pros and Cons

Thanks for the response in advance.

I'm waiting for the news to decide to investment or wait. LOTS of RAMPING going here

Buying on speculation and no news is gambling.

ITM Power has yet to achieve profitability, with significant losses reported in recent years. In the fiscal year 2024, the company reported a net income loss of £27 million, following a £101 million loss in 2023. The operating margin remains deeply negative, indicating ongoing financial strain.

The company's revenue has shown considerable volatility. For instance, in early 2023, the consensus revenue forecast was £25 million, but actual revenue ended up being just over £5 million—approximately 80% lower than expected.

Analysts at Barclays and JP Morgan have noted difficulties in scaling up production and have issued "underweight" ratings on ITM Power shares, citing these concerns.

I would not invest until ITM has clear strategy on long term profitability business - DYOR

Hugely undervalued - Going to rocket soon.

Current Share price doesn't make any sense on so much positive progress has been made.

The company is progressing with its drilling programs and awaiting the grant of a Mining License for its southern Rukwa Helium Project in Tanzania, which could unlock significant value for shareholders.

With a market cap of approximately £49 million and a share price currently trading around 0.85p, Helium presents an attractive entry point for investors looking to gain exposure to the helium sector. The company's strong project portfolio, solid financial position, and upcoming catalysts suggest significant huge upside potential. DYOR

SOLID NEWS - GREAT to see institutional sucked in now. Current share price is a joke. SOON WILL RE-RATE.

Company has achieved alot in where short time - HUGE POTENTIAL from here. Current Share price is a bargain.

From here - ONWARD AND UPWARDS

Big things are happening at Eurasia – and the market is starting to take notice. Geopolitical issue soon will resolve. When it flies - 3.5p is a dream for all.

I can see 40p very soon. Don’t have to wait too long

Groundbreaking findings in its preclinical research programme focused on P140, a candidate for treating autoimmune diseases. This discovery has attracted attention from global biopharma companies, indicating potential partnerships and collaborations. Advancements in research and strategic partnerships, ImmuPharma presents a compelling opportunity.

The Tulu Kapi Gold Project i– potentially unlocking a +1 million oz gold reserve and becoming Ethiopia’s first large-scale gold mine in decades. Early funding is in motion, community support is solid, and strategic partnerships are aligning.

Meanwhile, KEFI’s JV in Saudi Arabia is heating up fast. Massive exploration potential and early discoveries suggest multi-metal upside, not just gold.

The market’s starting to notice – but KEFI is still flying under many radars. With geopolitical risks reducing and funding progress accelerating, this could be one of AIM’s biggest sleepers about to wake up.

Tiny market cap. World-class assets. Near-term catalysts. You do the math -

Positive geopolical news definitely rerate Eurasia Mining, and serious eyes are back on the prize. With world-class platinum group metal assets in Russia and ongoing strategic discussions in the background, this quiet period might just be the calm before a major breakout. US investors - huge potential

The chart's shaping up, the fundamentals are still intact, and the long-term story remains unchanged—value is hiding in plain sight. The potential for asset monetisation or a game-changing partnership deal remains firmly on the table. At these levels, risk/reward looks incredibly attractive.

📈 40p is not just possible—it’s back on the cards. Strap in, because when EUA moves, it moves fast

As per previous message - Many reasons to go to sky.

Ready for Lift-Off!

With the groundbreaking progress on Lupus, ImmuPharma is poised for a major revaluation. The company’s innovative lupus treatment is entering advanced clinical trials, backed by a strong partnership with Avion Pharmaceuticals and FDA guidance. Early data has shown real promise—patients are entering remission without serious side effects, something rarely seen in autoimmune therapies.

This isn’t just another biotech story—ImmuPharma is addressing a global, underserved condition with multi-billion dollar market potential. With key milestones ahead, low current valuation, and positive trial momentum, the share price looks primed to fly from here.

Any positive update could be a game-changer. IMM could be the sleeper hit of the year

Ready for Lift-Off!

With the groundbreaking progress on Lupus, ImmuPharma is poised for a major revaluation. The company’s innovative lupus treatment is entering advanced clinical trials, backed by a strong partnership with Avion Pharmaceuticals and FDA guidance. Early data has shown real promise—patients are entering remission without serious side effects, something rarely seen in autoimmune therapies.

This isn’t just another biotech story—ImmuPharma is addressing a global, underserved condition with multi-billion dollar market potential. With key milestones ahead, low current valuation, and positive trial momentum, the share price looks primed to fly from here.

Any positive update could be a game-changer. IMM could be the sleeper hit of the year